FDA admits Sun’s appeal3 min read . Updated: 23 Nov 2007, 12:14 AM IST
FDA admits Sun’s appeal
FDA admits Sun’s appeal
Mumbai: US drugs regulator food and drug administration (FDA) has accepted a generic challenge by India’s Sun Pharmaceuticals Industries Ltd against Glivec, a controversial mega-earner cancer drug of Novartis AG, potentially weakening the Swiss drug maker’s petition against an Indian ruling denying the drug a patent.
The challenge in the US, if it invalidates Novartis’ patent, will not only significantly stre-ngthen the plea of local drug makers here, but also open up a huge generics market for them in the US for this drug, which, last year, grossed some $2.5 billion (Rs11,605 crore then), equivalent to more than one-10th?of?Novartis’?revenues.
Novartis’ patent on Glivec was challenged by Sun Pharma through what is called a Para IV filing with FDA. The filing initiates a process with which a generics firm can seek marketing approval for an already patented product either by invalidating the patent, by proving there is fundamentally nothing novel in the product or by proposing to introduce a variant without infringing the patent. The appeal was listed early this month by FDA after a six-month surveillance by the regulator. Under the rules, Novartis is expected to respond to this challenge within 45 days of the date of listing.
At least two drug industry insiders confirmed the Sun Pharma challenge and the FDA listing. The filing is likely aimed at invalidating the existing patent as the Mumbai drug maker has found gaps in Novartis’ patent.
An email sent to Novartis’ media relations office at Basel on Wednesday did not elicit any response and an India spokesperson said she was not authorized to comment.
An invalidation of the Glivec patent, if it happens through Sun Pharma’s Para IV filing, will help strengthen local drug makers’ claims against Novartis in India. “This very disclosure in the US will make Novartis’ appeal against the Chennai patent office’s decision to reject its patent application unacceptable," said Gopakumar Nair, a patent expert in Mumbai.
Shamnad Basheer, an associate at Oxford IP Research Center, UK, echoed this view. “If the US, which is comparatively liberal in granting patents, invalidates the Glivec patent, it will look ridiculous for any (of the) patent court(s) in the world, which are (usually) more cautious, to grant a patent for this drug," he said in a telephone interview.
Novartis has challenged the Indian patent office’s decision to turn down its patent application through an appeal filed early in 2006 in the Madras high court. The case has since shifted to the Intellectual Property Appellate Board, or IPAB, which hears such disputes in the country.
In 2006, the Chennai patent office refused Novartis’ patent claim for Glivec—which is a beta crystal or polymorphic form of the known cancer drug Imatinib Mesylate—on the ground that it is not an innovation and the Indian patent law does not identify this as patentable. One of the newly amended provisions in the Indian patent law, Section 3D, specifies that no derivatives or modified forms of known drug substances are patentable unless it enhances the therapeutic efficacy substantially.
Following the refusal of its patent application in India on this ground, Novartis challenged this provision of the Indian law, saying the rule is not compliant to World Trade Organization’s globally accepted patent law. This challenge was rejected by the Madras high court early this year.
Rajeev Nannapaneni, chief executive of Hyderabad-based Natco Pharma Ltd, which is one of the corporate opponents in Novartis’ patent dispute at IPAB, said: “The US patent challenge gives us a most important message that the Glivec patent has been questioned not only in India, but elsewhere also."
Meanwhile, Sun Pharma and Natco Pharma have also filed drug master files or DMFs with FDA for off-patent or generic versions of Glivec. Filing a DMF sets off the process for generic drug firms to get their products registered in the US pharmaceuticals market.
A Sun Pharma spokesman confirmed that the company has filed DMFs for six drugs in the US in April-June 2006, and one of them is the polymorph of imatinib, but declined further details on the Para IV filings.
(C.R. Sukumar in Hyderabad contributed to this story.)